

Metabolic profile and skin-related bioactivities of *Cerioporus squamosus* hydromethanolic extract

WAILL A. ELKHATEEB¹, GHOSON M. DABA^{1,✉}, MARWA O. ELNAHAS¹, PAUL W. THOMAS^{2,3},
MAHMOUD EMAM^{4,5,✉✉}

¹Chemistry of Natural and Microbial Products Department, Pharmaceutical Industries Division, National Research Centre, Dokki, Giza, 12622, Egypt. Tel. +201013241936, Fax.: +20233370931, ✉email: ghoson.daba@yahoo.com

²University of Stirling, Stirling, UK.

³Mycorrhizal Systems Ltd., Lancashire, UK.

⁴College of Pharmaceutical Science & Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou 310014, China. Tel. +201063802898, Fax.: +20233370931, ✉✉email: mahmoudemamhegazy2020@gmail.com

⁵Department of Phytochemistry and Plant Systematics, National Research Centre, 33 El Bohouth St., Dokki, Giza 12622, Egypt

Manuscript received: 12 July 2020. Revision accepted: 23 September 2020.

Abstract. Elkhateeb WA, Daba GM, Elnahas MO, Thomas PW, Emam M. 2020. Metabolic profile and skin-related bioactivities of *Cerioporus squamosus* hydromethanolic extract. *Biodiversitas* 21: 4732-4740. Being a functional food capable of showing nutritional as well as medicinal properties have great attention. Mushrooms have been proven as leading targets in this field. For this purpose, the edible mushroom *Cerioporus squamosus* was investigated in this study to evaluate the in vitro skin-related bioactivities of its hydromethanolic extract in terms of enhancing wound healing, and human skin cancer suppression capabilities. Treatment of fibroblast cells (BJ-1) with the hydromethanolic extract of this mushroom at 50 µg/mL enhanced cell migration rates by 71.7% after 24 h of exposure to the extract. Moreover, the same extract exhibited a promising impact on human skin cancer using an epidermoid carcinoma cell line (A431). The gradual increase in *C. squamosus* hydromethanolic extract concentration caused gradual decrease in the A431 cell viability and proliferation. Maximum effect on reducing the cell viability was obtained at a concentration of 100 µg/mL, where cell viability was 3.7%, and recorded IC₅₀ was 52.6 µg/mL. The metabolic profile of the extract was analyzed by GC-MS, which was performed on its silylated metabolites. Nineteen compounds were detected including sugar alcohols, amino acids, fatty and organic acids. Promising results of this mushroom extract encourage conducting further steps towards using this mushroom as a functional food showing promising bioactivities.

Keywords: GC-MS, edible mushroom, silylated metabolites, skin cancer, wound healing

INTRODUCTION

Without ignoring its functional roles in sensation and touch, the biofunctions of the largest human organ, the skin, include also protecting the body from losing excess water, and from external factors as sun, microbes. Moreover, the skin contribute principally in the process of body temperature regulation (James et al. 2011).

Skin injuries and wounds have a range of different etiologies and they should be healed as fast as possible in order to regain the lost tissues, allow the skin to continue its functions, and to continue tissue homeostasis. Wound healing and new tissue formation mechanisms are multistep complex processes that start with inflammation, then angiogenesis, followed by granulation tissue formation, re-epithelialization, and extracellular matrix reconstruction (Bolla et al. 2019). After a skin injury, immune cells quickly multiply, migrate to the injured location, and initiate wound healing mechanisms. Fibroblasts are the major cells existing in skin tissue, they rupture fibrin clots, generate extracellular matrix constituents as well as collagen structures that are needed for tissue homeostasis (Bainbridge 2013). Historically, a wide range of plant species was used for their wound healing properties and,

even today, wound healing pharmaceuticals which are based mainly on plants represent more than 70% of available products (Kumarasamyraja et al. 2012). Similarly, natural extracts originating from medicinal mushrooms have formed the basis of many studies, with a growing interest in identifying extracts potent as wound healing agents. *Ganoderma lucidum* (reishi mushroom), *Handkea utrifomis* (synonym of *Calvatia utrifomis*), *Hericium erinaceus*, *Morchella esculenta*, *Sparassis crispa*, and *Agaricus blazei* are among the fungi species that have previously shown promising wound healing abilities (Gupta et al. 2014; Elkhateeb et al. 2019c).

Malignant growths or tumors, resulting from uncontrolled cell division occur throughout the body and those that are specific to skin appear to be increasing, globally. Generally, there are two main types of skin cancer (melanoma and non-melanoma). Non-melanoma skin cancer is ranked as the 5th most commonly occurring cancer, accounting for an estimated 1.04 million deaths in 2018, while melanoma skin cancer is the 19th most commonly occurring cancer, and the incidences of non-melanoma and melanoma skin cancers have been increasing in recent decades (WHO Fact sheet, 2018). Generally, several mushroom species have shown

promising *in vitro* and *in vivo* abilities against cancer (Ivanova et al. 2014; Blagodatski et al. 2018; Ray et al. 2020). Very few mushrooms have been testified to have anti-skin cancer activities such as *Ganoderma lucidum*, and *Coriolus versicolor* (Chinembiri et al. 2014). *G. lucidum* extract has been demonstrated to have an anti-melanoma effect *in vitro*, and tumor-reducing activities *in vivo*. *G. lucidum* induces apoptosis (cancer cell death) and inhibits proliferation of skin cancer cells (Harhaji Trajković et al. 2009), while *C. versicolor* extract caused a reduction in growth of melanoma cells and tumor volume, through inhibiting cell proliferation and inducing apoptotic and necrotic cell death (Harhaji et al. 2008).

Screening for natural potent compounds that are capable of improving wound healing process and showing at the same time anti-skin cancer activity is attracting researcher's attention in modern pharmaceutical and biomedical sciences. Edible mushrooms are put under the scientific spotlight as they are already edible and can act as a source for bioactive compounds that may supplement and/or replace currently used drugs.

Cerioporus squamosus (Huds.) Quél. is a basidiomycetous edible mushroom, *C. squamosus* is generally known as dryad's saddle or pheasant's back mushroom and is usually existing in the northern temperate zones.

C. squamosus extracts have been evaluated for their potential biological activities and they have previously been reported to have antioxidant, wound healing, and antimicrobial activities (Zhao 2013; Fernandes et al. 2016; Mocan et al. 2018; Elkhateeb et al. 2019c). However, the anti-skin cancer activity of this promising mushroom has not been investigated before. In this study, we strive to explore the potential *in vitro* anti-skin cancer properties along with the wound healing potency of *C. squamosus* methanolic extract.

MATERIALS AND METHODS

Sample collection, identification, and extraction

For this study, whole fruiting bodies of *Cerioporus squamosus* (Huds.) Quél. (syn. *Polyporus squamosus* (Huds.) Fr.) were collected from the Isle of Bute, in Scotland (UK). Fruiting bodies were found growing in clusters and were readily identified as the target species, displaying a cap with the following properties: a fan-shape, broadly convex but becoming flat and shallowly depressed in older specimens. The caps were pale tan to creamy yellowish, with large and flattened, brown to blackish scales. Pores ran down the stem, whitish to creamy (white spore print), and displayed no bruising. Flesh was thick and moderately tough with a strongly mealy aroma (Figure 1). All samples were collected from the same tree host, which was a previously felled trunk of *Aesculus hippocastanum* (Sapindaceae). Which had become colonized with *C. squamosus* fruit bodies. *Cerioporus squamosus* identification was carried out using the morphological features according to Phillips (2013).

Samples were collected on the 1st of June 2018 and were immediately sliced and dried in a commercial heated dehydrator at approximately 75°C (GP-102-1, 250W, LASER 2000, Westfalia Werkzeug company GmbH & Co KG, Germany). After dehydration, samples were extracted as described previously (Elkhateeb et al. 2019d; Daba et al. 2020). Briefly, *C. squamosus* fruiting body pieces were placed in an Erlenmeyer flask containing 80% methanol at room temperature and kept overnight before filtering. The resulting filtered extract was concentrated at 37°C using a rotary evaporator. The obtained extract was stored at 4°C in a clean closed container until further use.



Figure 1. Fruiting bodies of *Cerioporus squamosus* collected from the Isle of Bute, in Scotland (UK). Photographs were taken by Dr. Paul W Thomas

Metabolic profile of *C. squamosus* hydromethanolic extract by GC-MS analysis

GC-MS analysis of silylated metabolites

Metabolite analysis was carried out as follows. Briefly, 100 mg of finely powdered *C. squamosus* was extracted with 5 mL 100% methanol with sonication for 30 min with frequent shaking, followed by centrifugation at 12,000×g for 10 min to remove debris. 100 µL of the methanolic extract was aliquoted in screw-cap vials and left to evaporate until complete dryness. For derivatization, 150 µL of N-methyl-N-(trimethylsilyl)-tri fluoroacetamide (MSTFA) that was previously diluted 1:1% with anhydrous pyridine added to the dried methanolic extract and incubated at 60°C for 45 min prior to analysis using GC-MS (Farak et al. 2018).

GC-MS analysis of *C. squamosus* extract

The GC-MS analysis of the extract was conducted as described by Elkhateeb et al. (2019d) using a TRACE GC Ultra Gas Chromatographs (THERMO Scientific Corp., USA), coupled with a thermo mass spectrometer detector (ISQ Single Quadrupole Mass Spectrometer). Helium was used during the analyses as carrier gas at a flow rate of 1.0 mL/min and a split ratio of 1:10. The program of temperature started with 60°C for 1 min; followed by rising temperature at 4.0 °C/min to 240 °C and held for 1 min. The injector and detector were held at 210°C. Diluted samples (1:10 hexane, v/v) of 1 µL of the mixtures were always injected. After that, mass spectra were measured by electron ionization (EI) at 70 eV, under a spectral range of m/z 40-450.

In vitro wound healing activity of *C. squamosus* hydromethanolic extract

The wound healing activity of *C. squamosus* hydromethanolic extract and the migration rates of BJ-1 cells were evaluated in the Bioassay-cell Culture Laboratory, National Research Center, Dokki, Egypt. using the scratch assay method. BJ-1 cell line is human skin fibroblast that is derived from normal foreskin and was obtained from American Type Culture Collection, ATCC® CRL-2522™, Manassas, VA, USA. The cell density of 2×10^5 cells were seeded into each well of a 24-well plate and incubated with complete medium at 37°C and 5% CO₂. After 24 h of incubation, the monolayer confluent cells were scrapped horizontally with a sterile P200 pipette tip. The debris was removed by washing with PBS. The cells were treated with *C. squamosus* methanolic extract at concentration 50, 100, 200 µg/mL. The cells without treatment were used as negative control. The induced scratch that represented the wound was photographed at 0 h using phase-contrast microscopy at ×40 magnification, before incubation with the samples. After 24 h of incubation, the second set of images was photographed. To determine the migration rate, the images were analyzed using "image J" software, and percentage of the closed area was measured and compared with the value obtained at 0 h. An increase in the percentage of the closed area was taken as an indication for the cell migration. Experiments were

performed in the triplicate and the data were recorded and analyzed statistically using SPSS 11.

$$\text{Wound closure (\%)} = \frac{(\text{Measurement at 0 h} - \text{Measurement after 24 h}) \times 100}{\text{Measurement at 0 h}}$$

In vitro anti-skin cancer activity of *C. squamosus* hydromethanolic extract

The in vitro anti-skin cancer study was performed in the Bioassay-cell culture laboratory, National Research Centre, Dokki, Egypt. Cell viability assay was assessed by the mitochondrial-dependent reduction of yellow MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) to reduced purple formazan (Mosmann 1983).

This experiment was conducted under sterile conditions via a Laminar flow cabinet biosafety class II level (Baker, SG403INT, Sanford, ME, USA). In this experiment, A431 cell line was used. A431 is human squamous cell carcinoma, A431 (ACC 91, DSMZ German collection of microorganisms and cell cultures, Braunschweig, Germany). First, skin cancer cells (A431) were suspended in DMEM-F12 medium, together with 1% antibiotic-antimycotic mixture (10,000 U/mL potassium penicillin, 10,000 µg/mL streptomycin sulfate and 25 µg/mL amphotericin B) and 1% L-glutamine. The experiment was conducted at 37 °C under 5% CO₂.

A431 skin cancer cells were batch cultured for 10 days, then at a concentration of 10^4 cells/well they were seeded in a fresh complete growth medium in 96-well microtiter plastic plates under 5% CO₂ at 37 °C for 24 hr using a water-jacketed carbon dioxide incubator (Sheldon, TC2323, Cornelius, OR, USA). Media was aspirated and then fresh medium (without serum) was added. The cells were incubated either alone (negative control) or with different concentrations of *C. squamosus* hydromethanolic extract with final concentrations of (12.5, 25, 50, and 100 µg/mL). The medium was aspirated after 48 hr of incubation and 40 µL MTT salt (2.5 µg/mL) were added to each well. Finally, the plates were incubated for four more hours under the same conditions.

Two hundred µL of 10% Sodium dodecyl sulfate (SDS) in deionized water was added after the end of incubation to each well then the plate was incubated overnight at 37°C. Adrinamycin® (Pharmacia India Pvt Ltd. Gurgaon, Haryana 122001, India) was used as a positive control (Thabrew et al. 1997), and medium free of tested extract was used as negative control. Color intensity was measured at 595 nm using a microplate multi-well reader (Bio-Rad Laboratories Inc., model 3350, Hercules, California, USA) and a reference wavelength of 620 nm. A statistical significance was tested between samples and negative control using independent t-test by SPSS 11 program. The change in viability percentage was calculated as following:

$$((A_s/A_c) - 1) \times 100$$

Where;

(A_s) is sample absorbance, and (A_c) is negative control absorbance. IC₅₀ was determined by SPSS 11 program.

RESULTS AND DISCUSSION

Metabolic profile identified from *C. squamosus* hydromethanolic extract

GC-MS analysis performed on the silylated metabolites originating from the hydromethanolic extract of *C. squamosus* fruiting bodies revealed detection of 19 compounds (Figure 2, Table 1). The total peak areas of the detected compounds were 70.76% and $SI \geq 750$, the probabilities of the structures of the detected compounds are listed in Table 1. The peak area% representing the sugar alcohol, xylitol, was the major peak (28.59%), followed by that of palmitic acid (17.43%), then glycerol (10.94%). The extract also contained amino acids such as alanine, L-valine, L-isoleucine, L-threonine. Moreover, many organic and fatty acids were detected such as D-lactic acid, oxalic acid, myristic acid, stearic acid, pentadecanoic acid, and dodecanoic acid (*lauric acid*). The

sugar alcohols - sorbitol, and erythritol were also identified in small peak areas of 3.01, and 0.22%, respectively.

In vitro wound healing activity of *C. squamosus* hydromethanolic extract towards human skin fibroblast ((BJ-1) cells

The effect of *C. squamosus* hydromethanolic extract on the migration of fibroblast cells (BJ-1) was investigated because cell migration plays a key role in wound repair and healing. As shown in Figures 3, and 4 after 24 h of exposure to *C. squamosus* hydromethanolic extract, cells migrated towards the provisional gap induced. Migration analysis values showed that 50 $\mu\text{g/mL}$ of the *C. squamosus* extract was the concentration causing the highest increase in cell migration (71.7%). Further increase in extract concentration was accompanied with decrease in migration rate until reached 3.24% after 24 h of exposure to a concentration of 200 $\mu\text{g/mL}$ of the mushroom extract.




Figure 2. GC-MS chromatogram of the silylated metabolites originated from *Ceriporus squamosus* hydromethanolic extract




Figure 3. The percentage of migration rate for BJ-1 cells after 24 h of treatment with *Ceriporus squamosus* hydromethanolic extract.

Table 1. Identified compounds of silylated *Ceriporus squamosus* extract using GC-MS

No.	RT	Area %	Compound name	Molecular weight	Molecular formula	SI
1	4.89	0.24	Alanine	89	C ₃ H ₇ NO ₂	860
2	5.40	0.30	Ethanedioic acid (Oxalic acid)	90	C ₂ H ₂ O ₄	752
3	6.94	0.34	L-Valine	117	C ₅ H ₁₁ NO ₂	868
4	8.00	10.94	Glycerol	92	C ₃ H ₈ O ₃	927
5	8.42	0.28	L-Isoleucine	131	C ₆ H ₁₃ NO ₂	880
6	10.10	0.24	L-Threonine	119	C ₄ H ₉ NO ₃	824
7	12.06	0.22	Erythritol	122	C ₄ H ₁₀ O ₄	920
8	12.18	0.69	meso-Erythritol	122	C ₄ H ₁₀ O ₄	931
9	13.77	0.13	2-Deoxyribose	136	C ₅ H ₁₂ O	834
10	15.05	2.08	Dodecanoic acid	200	C ₁₂ H ₂₄ O ₂	911
11	15.58	28.59	Xylitol	152	C ₅ H ₁₂ O ₅	927
12	16.88	0.33	D-Psicofuranose	180	C ₆ H ₁₂ O	850
13	18.08	2.07	Tetradecanoic acid (Myristic acid)	228	C ₁₄ H ₂₈ O ₂	898
14	18.59	3.01	sorbitol (glucitol)	182	C ₆ H ₁₄ O ₆	901
15	18.68	0.20	2,2'-oxybis(ethan-1-ol)	106	C ₄ H ₁₀ O ₃	753
16	19.52	0.74	Pentadecanoic acid	242	C ₁₅ H ₃₀ O ₂	740
17	20.85	17.43	Hexadecanoic acid (Palmitic Acid)	256	C ₁₆ H ₃₂ O ₂	866
18	23.10	2.34	2-hydroxy Propanoic acid (D-lactic acid)	90	C ₃ H ₆ O ₃	779
19	23.44	0.59	Octadecanoic acid (Stearic Acid)	284	C ₁₈ H ₃₆ O ₂	759

Note: Total identified % is 70.76 and $SI \geq 750$




Figure 4. Wound healing ability of *Cerioporos squamosus* hydromethanolic extraction to BJ-1 cells. Images were acquired at (A) 50 µg/mL 0 h, and (B) 50 µg/mL after 24 h of exposure to extract. (C) 100 µg/mL 0 h, and (D) 100 µg/mL after 24 h of exposure to extract. (E) 200 µg/mL 0 h and (F) 200 µg/mL after 24 h of exposure to extract. Images were analyzed using “image J” software, and percentage of the closed area was measured and compared with the value obtained at 0 h

Effect of *C. squamosus* hydromethanolic extract on the viability of A431 human squamous cell carcinoma skin cancer cell line

The viability or the proliferation of the skin cancer cell line (A431) was tested by the MTT assay (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide). This is a colorimetric assay that measures cell metabolic activity. Here, NAD(P)H-dependent cellular oxidoreductase enzymes, which is an indicator of the cell viability, was measured. The function of this enzyme is to reduce the tetrazolium dye of the MTT which in turn forms an insoluble purple colored formazan that dissolved in acidified alcohol and finally measured at 595 nm.

Using the MTT assay, different concentrations of the *C. squamosus* hydromethanolic extract (12, 25, 50, 100 µg/mL) were examined to evaluate their capabilities to inhibit A431 skin cancer cell proliferation. Results shown in Figure 5 revealed the promising effect of the mushroom extract on reducing A431 cell proliferation. This appeared as a gradual decrease in cell viability with the gradual increase of *C. squamosus* hydromethanolic extract concentration (Figure 6). The maximum cell viability reducing ability was obtained using a concentration of 100 µg/mL recording a cell viability % of 3.7, and the IC₅₀ was found to be 52.6 µg/mL.




Figure 5. A. A431 skin cancer cell line before treatment with *C. squamosus* hydromethanolic extract. B. A431 skin cancer cell line after treatment with 100 µg/mL of *Cerioporus squamosus* hydromethanolic extract for 48 h




Figure 6. *Cerioporus squamosus* hydromethanolic extract reduced the proliferation of A431 skin cancer cells. A431 cells were cultured in the presence of 0, 12.5, 25, 50, and 100 µg/mL of the extract for 48 h and followed by measuring the cell viability via MTT assay. Error bars represent mean \pm SD where * $p \leq 0.05$; ** $p \leq 0.01$; *** $p \leq 0.001$; **** $p \leq 0.0001$ indicates a significant decrease over 0 µg/mL concentration

Discussion

Mushrooms are generous sources of metabolites with promising bioactivities. Moreover, being edible encourages further investigation to authorize their application in medicines and pharmaceuticals. Studies on many mushroom species such as *Ganoderma lucidum*, *Cordyceps militaris*, *Hericium erinaceus*, *Metacordyceps neogunnii* (Synonym of *Keithomyces neogunnii*), and *Dictyophora indusiata* revealed their potent in vitro biological capabilities as anticoagulant, antiviral, hypocholesterolemic, anti-colon cancer, and antioxidant agents (Elkhateeb et al. 2019b; Elkhateeb et al. 2019c; El-Hagrassi et al. 2020; Daba et al. 2020). Furthermore, some mushrooms have promising wound healing activities (Buko et al. 2019; Elkhateeb et al. 2019c; Kosanić et al. 2020). *Cerioporus squamosus* is an edible, basidiomycetous mushroom that is rich in macronutrients, organic acids, fatty acids and other important compounds (Elkhateeb et al. 2019a). Additionally, *C. squamosus* has been used as medicine for

its diuretic, antimicrobial, cytotoxic, immuno-enhancing, anti-inflammatory, hepatoprotective, nephroprotective, antioxidant activities, and stimulate hair growth (Daskocil et al. 2016; Fernandes et al. 2016; Elkhateeb et al. 2019a).

Understanding the effects of *C. squamosus* extract on mammalian cells is required, to provide the basis for the development of a novel and safe product useful for treatment of various diseases. In this study, the wound healing, and anti-human skin cancer activities of the hydromethanolic extract of *C. squamosus* were investigated. Moreover, chemical analysis was performed on the hydromethanolic *C. squamosus* methanolic extract in order to detect its bioactive metabolites.

The in vitro evaluation of the anticancer activity of *C. squamosus* hydromethanolic extract against epidermoid carcinoma A431 cell line revealed its promising anticancer effect, which showed its optimum action after treatment with extract at concentration of 100 µg/mL where the cell viability was 3.7%.

It is important to mention that the current work represents the first study investigating the effect of *C. squamosus* hydromethanolic extract on human skin cancer cell lines. As shown from the GC-MS analysis of the sialylated metabolites originated from *C. squamosus* extract, 19 compounds were detected and listed in table 1. More than quarter of the area percentage of the total detected metabolites (28.59%) was occupied by xylitol - sugar alcohol. Xylitol has various biological activities and is used most commonly in oral hygiene products due to its anti-inflammatory and anticaries characteristics (Nayak et al. 2014). Many in vitro studies on cancer cell lines have elucidated the dose-dependent inhibitory role of xylitol on cell proliferation, which is suggested to be achieved through autophagy (Park et al. 2015).

Moreover, a recent study had suggested that partial substitution of glucose with sugar alcohols especially xylitol could deeply suppress proliferation of oral cancer but not non-transformed cells (Trachootham et al. 2017). One of the highly detected metabolites in *C. squamosus* hydromethanolic extract is palmitic acid (representing 17.43 area %). Long-chain fatty acids, such as palmitic acid, were testified in many studies to have cytotoxic and antiproliferative activities against cancer cells by inhibiting DNA topoisomerase I and inducing

apoptosis in human leukemic cells (Harada et al. 2002; Ravi and Krishnan 2017). Glycerol, which is also detected in *C. squamosus* extract (10.94%), has inhibitory effects on growth and invasion of some human cancer cell lines (Sakurai et al. 2011). Interestingly, the majority of remaining compounds detected in the hydromethanolic extract of *C. squamosus* have also been reported to have anti-cancer properties. Sorbitol has anticancer activities against several tumor models (Lu et al. 2014) through inducing apoptosis in an efficient and rapid way when provided at high concentrations as a part of hyperosmotic stress mechanisms (Marfè et al. 2008). Sorbitol was reported in many studies for its ability to activate the p38 MAPK signal transduction pathway and induce the apoptosis of tumor cells (Marfè et al. 2008). Additionally, the medium-chain length fatty acid, dodecanoic acid, which is known also as lauric acid has well reported anticancer activity (Sandhya et al. 2016). In previous in vitro studies, lauric acid has induced apoptosis in colon cancer cells due to oxidative stress (Fauser et al. 2013). Also, lauric acid has induced cell death in colon cancer cells settled by the epidermal growth factor receptor down-regulation (Sheela et al. 2019).

Generally, the overall pattern obtained after many in vitro studies on different cell lines revealed that even the lauric acid-containing derivatives were the most effective anticancer agent (Chhikara et al. 2011). On the other hand, several studies have suggested that selective amino acid deprivation of serine and glycine or phenylalanine and tyrosine can inhibit tumor growth in animal models (Maddocks et al. 2017). Alanine and glutamic acid-induced apoptosis of gastric cancer cells (Gu et al. 2015), β -alanine exhibited a co-therapeutic activity in the treatment of breast tumors and reduced cancerous metabolism besides reducing extracellular acidification which leads to suppressed aggressiveness. Also, β -alanine increased the efficacy of Dox on MCF-7 cells at low concentrations (Vaughan et al. 2014). Oxalic acid, which was also one of the metabolites detected in the extract, has been reported for its therapeutic effect for controlling, and treating, neoplasia, tumors, including brain tumors, and for preventing the new growth of different or abnormal tissues (Hart et al. 2000). However, it should be noted that some studies have reported the ability of oxalate to induce breast cancer when injected into mice mammary fat pad (Castellaro et al. 2015).

It is worth noting that cancer patients (including skin cancer patients) are subjected to various physiological changes including the process of the disease itself, treatment course, social situation as well as poor nutritional status and in combination, these factors may contribute to delay of wound healing processes (Payne et al. 2008).

Wound healing is an important biological mechanism that occurs in the human body and includes the well-regulated steps; hemostasis, inflammation, proliferation, and finally remodelling (Guo and DiPietro 2010). Several factors can interfere with one or more of these process steps resulting in impaired or delayed wound healing, such as diabetes mellitus, hypertension, venous stasis disease,

cancer disease as well as some treatments, age-related health issues, and nutritional status (Menke et al. 2007).

A 2018 analysis of Medicare beneficiaries in the USA reported about 8.2 million (14.5%) suffered from wounds including both infected and non-infected (By microorganisms). Moreover, the Medicare cost estimated for curing these wounds ranged from \$28.1 billion to \$96.8 billion. It is expected that the annual cost for medical products for wound care alone, could reach \$15–22 billion by 2024 (Sen 2019). Hence, it is crucial to find new low-cost wound treatments primarily originating from natural sources with low toxicity and minimal side effects.

Nowadays, the interest of many scientists has been directed to phytomedicine due to the demonstrated ability of many plants to aid in the healing of wounds. However, little is known about the wound healing properties of mushrooms to heal wounds (Elkhateeb et al. 2019c). So, we were interested to evaluate the ability of *C. squamosus* mushrooms to treat wounds via the scratch assay in order to develop a natural product that promotes wound healing in cancer patients and specifically “skin cancer patients”. The results showed that promising anti-skin cancer effect, especially helpful to the cancer patients suffering from delayed and impaired wound healing.

The effect of *C. squamosus* hydromethanolic extract on the migration of BJ-1 normal human fibroblast cells was tested, where different concentrations of *C. squamosus* hydromethanolic extract (ranging from 50–200 μ g/mL) were added to BJ1 monolayer confluent cells and it was found that the extract exhibits an obvious effect on wound healing where the migration rate at the concentration of 50 μ g/mL was 71.7%. However, any further increase in the extract concentration (beyond 50 μ g/mL) was accompanied by gradual decrease in migration rate until it reached the level of 3.24% at the concentration of 200 μ g/mL after 24 hours of incubation. As the lowest tested concentration displayed the highest migration rate, it remains possible that the optimal concentration level may be below 50 μ g/mL and further investigation will be needed to identify this optimum.

The results obtained from GC-MS may help explain these results. The obtained profile of the analyzed hydromethanolic extract contains 19 compounds that are classified into different groups. They are mainly amino acids, sugar alcohols, fatty acids, and carbohydrates (see table 1). Lately, some studies have focused on examining the roles of various immune nutrients such as amino acids, fatty acids, and minerals on wound healing (Silva et al. 2018).

Our results showed the presence of four amino acids: alanine, L-valine, L-isoleucine, and L-threonine. Many of amino acids play a vital role in building and repairing human body tissues and are therefore pivotal in wound healing. The human body can create some of these amino acids but not all of them and the deficit must be supplied from foods (Council 1989).

Arginine (detected in *C. squamosus* extract) is well known for its great role in wound healing. Arginine accelerates insulin secretion, promotes protein regeneration, and helps transport amino acids into the cells.

It is worth mentioning that 32% of arginine is nitrogen and it is the only producer of nitric oxide. Nitric oxide is an important role in wound healing as it increases blood flow and oxygen supply to the wound and also increasing collagen formation (Williams et al. 2002) and limiting the inflammation process. Being an edible mushroom, *C. squamosus* could be very helpful in wound healing. Moreover, some studies showed that L-valine, L-isoleucine, and L-threonine also promote the wound healing process and these are also amino acids that cannot be produced by the human body. Branched amino acids such as L-valine and L-isoleucine are crucial in building muscles and hence wound healing, and these two amino acids are different than others in that they are metabolized in the muscle and not in the liver (Stengler 2010). Amino acids are found in different forms, however, the optimum form utilized by the human body is the L-form (Stengler 2010), which is the principal form present in *C. squamosus* extract and further supports the conclusion that the present extract is a very promising aid to wound healing.

Several fatty acids were also detected in the *C. squamosus* extract. Fatty acids are generally classified on the basis of the presence of double bonds into saturated (no double bonds) and unsaturated (with double bonds) fatty acids (Calder 2011; Silva et al. 2018). Some fatty acids may have a role in healing processes. In a previous study, treatment of a Zebrafish (*Danio rerio*) model with linoleic acid containing lucuma nut oil, accelerated cell regeneration. This may be attributed to increasing angiogenesis, resuming the oxygen and nutrient supply which in turn promotes wound healing (Silva et al. 2018). Taken together, our results showed that *C. squamosus* could be a promising treatment with dual action for skin cancer patients who suffer from impaired wound healing, thus limiting the viability of skin cancer cells as well as triggering normal cells to heal.

Having a multi-functional natural source of bioactive compounds is a property of high demand. Especially so, if this source is already an edible one with a history of use by people for its nutritional and medical capabilities. *C. squamosus* hydromethanolic extract has shown promising in vitro skin-related bioactivities with potent anti-skin cancer and wound healing abilities. Results presented in this study encourage further investigation in order to evaluate the *in vivo* potentials of this extract. As far as we know, this is the first study that describes a significant impact on human skin cancer activity by *C. squamosus* hydromethanolic extract. Moreover, this work represents a significant step toward evaluating the real therapeutic potential of the edible mushroom *C. squamosus*.

REFERENCES

- Bainbridge P. 2013. Wound healing and the role of fibroblasts. *J Wound Care* 22 (8): 407-408, 410-412. DOI: 10.12968/jowc.2013.22.8.407.
- Blagodatski A, Yatsunskaya M, Mikhailova V, Tiasto V, Kagansky A, Katanaev VL. 2018. Medicinal mushrooms as an attractive new source of natural compounds for future cancer therapy. *Oncotarget* 9 (49): 29259-29274. DOI: 10.18632/oncotarget.25660.
- Buko V, Bakunovich A, Astrowski A, Moroz V, Puchkova T, Kastsianevich A, Tomulewicz M. 2019. Polysaccharides of mushroom *Phallus impudicus* mycelium: Immunomodulating and wound healing properties. *Modern Food Sci Technol* 35: 30-37.
- Bolla SR, Al-Subaie AM, Al-Jindan RY, Balakrishna JP, Ravi PK, Veeraraghavan VP, Pillai AA, Gollapalli SSR, Joseph JP, Surapaneni KM. 2019. In vitro wound healing potency of methanolic leaf extract of *Aristolochia saccata* is possibly mediated by its stimulatory effect on collagen-I expression. *Heliyon* 5 (5): e01648. DOI: 10.1016/j.heliyon.2019.e01648
- Calder PC. 2011. Fatty acids and inflammation: The cutting edge between food and pharma. *Eur J Pharmacol* 668 (1): S50-S58. DOI: 10.1016/j.ejphar.2011.05.085
- Phillips R. 2013. Mushrooms: A comprehensive guide to mushroom, identification. Macmillan publisher limited, Oxford, UK.
- Castellaro AM, Tonda A, Cejas HH, Ferreyra H, Caputto BL, Pucci OA, Gil GA. 2015. Oxalate induces breast cancer. *BMC Cancer* 15: 761. DOI: 10.1186/s12885-015-1747-2.
- Chhikara BS, Jean NS, Mandal D, Kumar A, Parang K. 2011. Fatty acyl amide derivatives of doxorubicin: Synthesis and in vitro anticancer activities. *Eur J Med Chem* 46 (6): 2037-2042. DOI: 10.1016/j.ejmech.2011.02.056
- Chinembiri TN, Du Plessis LH, Gerber M, Hamman JH, Du Plessis J. 2014. Review of natural compounds for potential skin cancer treatment. *Molecules* 19 (8): 11679-11721. DOI: 10.3390/molecules190811679
- Council NR. 1989. Recommended dietary allowances (10th Edition). National Research Council (US) Subcommittee on the Tenth Edition of the Recommended Dietary Allowances. National Academies Press, Washington, USA.
- Daba GM, Elkhateeb W, Negm EL-Dien A, Ahmed EF, El-Hagrasi AM, Fayad W, Wen TC. 2020. Therapeutic potentials of n-hexane extracts of the three medicinal mushrooms regarding their anti-colon cancer, antioxidant, and hypocholesterolemic capabilities. *Biodiversitas* 21 (6): 2437-2445. DOI: 10.13057/biodiv/d210615
- Doskocil I, Havlik J, Verlotta R, Tauchen J, Vesela L, Macakova K, Rada V. 2016. In vitro immunomodulatory activity, cytotoxicity and chemistry of some central European polypores. *Pharm Biol* 54 (11): 2369-2376. DOI: 10.3109/13880209.2016.1156708
- El-Hagrassi A, Daba G, Elkhateeb W, Ahmed E, Negm El Dien A, Fayad W, Shaheen M, Shehata R, El-Manawaty M, Wen TC. 2020. In vitro bioactive potential and chemical analysis of the n-hexane extract of the medicinal mushroom, *Cordyceps militaris*. *Malays J Microbiol* 16: 40-48.
- Elkhateeb W, A, Daba GM, Elnahas MO, Thomas PW. 2019a. *Fomes fomentarius* and *Polyporus squamosus* models of marvel medicinal mushrooms. *Egypt Pharm J* 18: 285-289.
- Elkhateeb W, El-Sayed H, Fayad W, Al Kolaibe AG, Emam M, Daba G. 2020. In vitro Anti-breast cancer and antifungal Bio-efficiency of some microalgal extracts. *Egypt J Aquat Biol Fish* 24: 263-279.
- Elkhateeb WA, Daba GM, Elnahas MO, Thomas PW. 2019b. Anticoagulant Capacities of Some Medicinal Mushrooms. *ARC J Pharma Sci* 5: 12-16.
- Elkhateeb WA, Daba GM, Sheir D, El-Dein AN, Fayad W, Elmahdy EM, Shaheen MN, Thomas PW, Wen TC. 2019d. GC-MS analysis and *in-vitro* hypocholesterolemic, anti-rotavirus, anti-human colon carcinoma activities of the crude extract of a Japanese *Ganoderma* spp. *Egypt Pharma J* 18: 102-110.
- Elkhateeb WA, Elnahas MO, Thomas PW, Daba GM. 2019c. To heal or not to heal? Medicinal mushrooms wound healing capacities. *ARC J Pharma Sci* 5: 28-35.
- Farag MA, Mohsen E, El-Gendy ANG. 2018. Sensory metabolites profiling in *Myristica fragrans* (Nutmeg) organs and in response to roasting as analyzed via chemometric tools. *LWT* 97: 684-692. DOI: 10.1016/j.lwt.2018.08.002
- Fausser JK, Matthews GM, Cummins AG, Howarth GS. 2013. Induction of apoptosis by the medium-chain length fatty acid lauric acid in colon cancer cells due to induction of oxidative stress. *Chemotherapy* 59 (3): 214-224. DOI: 10.1159/000356067
- Fernandes A, Petrović J, Stojković D, Barros L, Glamočlija J, Soković M, Martins A, Ferreira ICFR. 2016. *Polyporus squamosus* (Huds.) Fr from different origins: Chemical characterization, screening of the bioactive properties and specific antimicrobial effects against *Pseudomonas aeruginosa*. *LWT-Food Sci Technol* 69: 91-97. DOI: 10.1016/j.lwt.2016.01.037
- Gu Y, Chen T, Fu S, Sun X, Wang L, Wang J, Lu Y, Ding S, Ruan G, Teng L, Wang M. 2015. Perioperative dynamics and significance of

- amino acid profiles in patients with cancer. *J Transl Med* 13: 35. DOI: 10.1186/s12967-015-0408-1
- Guo S, DiPietro LA. 2010. Factors affecting wound healing. *J Dent Res* 89 (3): 219-229. DOI: 10.1177/0022034509359125.
- Gupta A, Kirar V, Keshri GK, Gola S, Yadav A, Negi PS, Misra K. 2014. Wound healing activity of an aqueous extract of the Lingzhi or Reishi medicinal mushroom *Ganoderma lucidum* (Higher Basidiomycetes). *Int J Med Mushrooms* 16: 345-354.
- Harada H, Yamashita U, Kurihara H, Fukushi E, Kawabata J, Kamei Y. 2002. Antitumor activity of palmitic acid found as a selective cytotoxic substance in a marine red alga. *Anticancer Res* 22: 2587-2590.
- Harhaji LJ, Mijatović S, Maksimović-Ivanić D, Stojanović I, Momčilović M, Maksimović V, Tufegdžić S, Marjanović Ž, Mostarica-Stojković M, Vučinić Ž, Stojić-Grujić S. 2008. Anti-tumor effect of *Coriolus versicolor* methanol extract against mouse B16 melanoma cells: in vitro and in vivo study. *Food Chem Toxicol* 46 (5): 1825-1833. DOI: 10.1016/j.fct.2008.01.027
- Harhaji Trajković LM, Mijatović SA, Maksimović-Ivanić DD, Stojanović ID, Momčilović MB, Tufegdžić SJ, Maksimović VM, Marjanović ŽS, Stojić-Grujić SD. 2009. Anticancer properties of *Ganoderma lucidum* methanol extracts in vitro and in vivo. *Nutr Cancer* 61: 696-707. DOI: 10.1080/01635580902898743
- Hart FJ. 2000. Oxalic acid or oxalate composition and method of treatment. U.S. Patent 6133317A, available at <https://patents.google.com/patent/US6133317A>, accessed on 31.08.2020.
- Ivanova TS, Krupodorova TA, Barshteyn VY, Artamonova AB, Shlyakhovenko VA. 2014. Anticancer substances of mushroom origin. *Exp Oncol* 36: 58-66.
- James WD, Elston D, Berger, T. 2011. *Andrew's Diseases of the Skin E-Book: Clinical Dermatology*, 11th Edition. Saunders, Elsevier, USA.
- Kosanić MM, Šeklić DS, Jovanović MM, Petrović NN, Marković SD. 2020. *Hygrophorus eburneus*, edible mushroom, a promising natural bioactive agent. *EXCLI J* 19: 442-457. DOI: 10.17179/excli2019-2056
- Kumarasamyraja D, Jeganathan N, Manavalan R. 2012. A review on medicinal plants with potential wound healing activity. *Int J Pharm Pharm Sci* 2: 101-107.
- Lu X, Li C, Wang YK, Jiang K, Gai XD. 2014. Sorbitol induces apoptosis of human colorectal cancer cells via p38 MAPK signal transduction. *Oncol Lett* 7 (6): 1992-1996. DOI: 10.3892/ol.2014.1994
- Maddocks ODK, Athineos D, Cheung EC, Lee P, Zhang T, van den Broek NJF, Mackay GM, Labuschagne CF, Gay D, Kruiswijk F, Blagih J, Vincent DF, Campbell KJ, Ceteci F, Sansom OJ, Blyth K, Voudsen KH. 2017. Modulating the therapeutic response of tumours to dietary serine and glycine starvation. *Nature* 544 (7650): 372-376. DOI: 10.1038/nature22056
- Marfè G, Morgante E, Di Stefano C, Di Renzo L, De Martino L, Iovane G, Russo MA, Sinibaldi-Salimei P. 2008. Sorbitol-induced apoptosis of human leukemia is mediated by caspase activation and cytochrome c release. *Arch Toxicol* 82 (6): 371-377. DOI: 10.1007/s00204-007-0261-y
- Menke NB, Ward KR, Witten TM, Bonchev DG, Diegelmann RF. 2007. Impaired wound healing. *Clin Dermatol* 25 (1): 19-25. DOI: 10.1016/j.clindermatol.2006.12.005
- Mocan A, Fernandes Â, Barros L, Crişan G, Smiljković M, Soković M, Ferreira ICFR. 2018. Chemical composition and bioactive properties of the wild mushroom *Polyporus squamosus* (Huds.) Fr: A study with samples from Romania. *Food Funct* 9 (1): 160-170. DOI: 10.1039/c7fo01514c
- Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. *J Immunol Methods* 65 (1-2): 55-63. DOI: 10.1016/0022-1759(83)90303-4
- Nayak PA, Nayak UA, Khandelwal V. 2014. The effect of xylitol on dental caries and oral flora. *Clin Cosmet Investig Dent* 6: 89-94. DOI: 10.2147/CCIDE.S55761
- Park E, Park MH, Na HS, Chung J. 2015. Xylitol induces cell death in lung cancer A549 cells by autophagy. *Biotechnol Lett* 37: 983-990. DOI: 10.1007/s10529-014-1757-1
- Payne WG, Naidu DK, Wheeler CK, Barkoe D, Mentis M, Salas RE, Smith Jr DJ, Robson MC. 2008. Wound healing in patients with cancer. *Eplasty* 8: 68-90.
- Ravi L, Krishnan K. 2017. Cytotoxic potential of N-hexadecanoic acid extracted from *Kigelia pinnata* leaves. *Asian J Cell Biol* 12: 20-27.
- Ray R, Pal A, Paul S. 2020. Assessment of the impact of wild stinkhorn mushroom extracts on different cancer cell proliferation and study of primary metabolites. *Phcog J* 12: 699-708.
- Sakurai S, Okada Y, Mataga I. 2011. Inhibitory effects of glycerol on growth and invasion of human oral cancer cell lines. *J Hard Tissue Biol* 20: 37-46.
- Sandhya S, Talukdar J, Bhaishya D. 2016. Chemical and biological properties of lauric acid: A review. *Int J Adv Res* 4: 1123-1128.
- Sen CK. 2019. Human wounds and its burden: an updated compendium of estimates. *Adv Wound Care (New Rochelle)* 8 (2): 39-48. DOI: 10.1089/wound.2019.0946
- Sheela DL, Narayanankutty A, Nazeem PA, Raghavamenon AC, Muthangaparambil SR. 2019. Lauric acid induces cell death in colon cancer cells mediated by the epidermal growth factor receptor downregulation: An in silico and in vitro study. *Hum Exp Toxicol* 38 (7): 753-761. DOI: 10.1177/0960327119839185
- Silva JR, Burger B, Kühl CMC, Candrea T, dos Anjos MBP, Rodrigues HG. 2018. Wound healing and omega-6 fatty acids: From inflammation to repair. *Mediators Inflamm* 2018: 2503950. DOI: 10.1155/2018/2503950
- Stengler M. 2010. *The Natural Physician's Healing Therapies: Proven Remedies Medical Doctors Don't Know*, Penguin, Canada.
- Thabrew MI, Hughes RD, McFarlane IG. 1997. Screening of hepatoprotective plant components using a HepG2 cell cytotoxicity assay. *J Pharm Pharmacol* 49 (11): 1132-1135. DOI: 10.1111/j.2042-7158.1997.tb06055.x
- Trachootham D, Chingsuwanrote P, Yoosadiang P, Mekkiangkrai D, Ratchawong T, Buraphacheep N, Kijankul S, Saekhow S, Pongpichayadej O, Vongvachvasin K, Sittikornpaiboon P, Tuntipopopat S. 2017. Partial substitution of glucose with xylitol suppressed the glycolysis and selectively inhibited the proliferation of oral cancer cells. *Nutr Cancer* 69 (6): 862-872. DOI: 10.1080/01635581.2017.1339097
- Vaughan RA, Gannon NP, Garcia-Smith R, Licon-Munoz Y, Barberena MA, Bisoffi M, Trujillo KA. 2014. β -alanine suppresses malignant breast epithelial cell aggressiveness through alterations in metabolism and cellular acidity in vitro. *Mol Cancer* 13: 14. DOI: 10.1186/1476-4598-13-14
- Williams JZ, Abumrad N, Barbul A. 2002. Effect of a specialized amino acid mixture on human collagen deposition. *Ann Surg* 236 (3): 369-375. DOI: 10.1097/0000658-200209000-00013
- World Health Organization, Fact sheet: Cancer. 2018. WHO: Geneva, Switzerland. <https://www.who.int/news-room/fact-sheets/detail/cancer>. [12 September 2018].
- Zhao YY. 2013. Traditional uses, phytochemistry, pharmacology, pharmacokinetics and quality control of *Polyporus umbellatus* (Pers.) Fries: A review. *J Ethnopharmacol* 149 (1): 35-48. DOI: 10.1016/j.jep.2013.06.031.